Vanda Pharmaceuticals's revenue for the
three
months ended in Mar. 2024 was €43.7 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €164.1 Mil.
Vanda Pharmaceuticals's Revenue per Share for the
three
months ended in Mar. 2024 was €0.76.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €2.85.
Warning Sign:
Vanda Pharmaceuticals Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Vanda Pharmaceuticals was -25.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -9.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -0.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 12.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Vanda Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 90.40% per year. The lowest was -9.40% per year. And the median was 8.10% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vanda Pharmaceuticals's Revenue
For the Biotechnology subindustry, Vanda Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanda Pharmaceuticals's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where Vanda Pharmaceuticals's Revenue falls into.
Vanda Pharmaceuticals Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €164.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Vanda Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Vanda Pharmaceuticals (FRA:VM4) Business Description
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:VM4 has been successfully added to your 